

experimental data to support the experimental hypothesis. Specifically:

1. ORI found falsified and/or fabricated data in Paper 1 in:
  - a. Figure 5B by manipulation of the HER3 protein concentrations in the experiment to provide the desired outcome
  - b. Figure 6C for the identification of the kinase domain construct EGFR–V924R by falsely claiming that both EGFR and HER3 contained the kinase domains and the full JM segments, when the JM–HER3 construct included cloning tags
  - c. Figure 6D by manually manipulating the error bars to increase statistical significance of the kinase assay
2. ORI found falsified and/or fabricated data in Paper 2 in:
  - a. Figure 3C by manually altering some of the data points by 10–20% support the desired hypothesis
  - b. Figure 4A by manipulating data points and reducing error bars and failing to report that JM–HER3 construct had cloning tags
  - c. Figure 4B by reducing several data points by ~ 15%

Mr. Littlefield has entered into a Voluntary Settlement Agreement and has voluntarily agreed:

(1) To have his research supervised for period of three (3) years beginning on August 4, 2015; Respondent agreed that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which his participation is proposed and prior to his participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of his duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of his research contribution; Respondent agreed that he will not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan;

(2) that for period of three (3) years beginning on August 4, 2015, any institution employing him shall submit in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived, and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract;

(3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for period of three (3) years beginning on August 4, 2015; and (4) to retraction or correction of the following papers:

- *Science Signaling* 7:ra114, 2014
- *Chemistry & Biology* 21:453–458, 2014

**FOR FURTHER INFORMATION CONTACT:**

Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200.

**Donald Wright,**

*Acting Director, Office of Research Integrity.*

[FR Doc. 2015–21421 Filed 8–28–15; 8:45 am]

**BILLING CODE 4150–31–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01).

*Date:* September 25 and 28, 2015.

*Time:* September 25, 2015, 12:30 p.m. to 4:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health; Room 3F52B; 5601 Fishers Lane; Rockville, MD 20892; (Telephone Conference Call).

*Time:* September 28, 2015, 9:30 a.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health; Room 3F52B; 5601 Fishers Lane; Rockville, MD 20892; (Telephone Conference Call).

*Contact Person:* Nancy Vazquez-Maldonado, Ph.D., Scientific Review Officer;

Scientific Review Program; Division of Extramural Activities, Room 3F52B; National Institutes of Health/NIAID; 5601 Fishers Lane, MSC 9823; Bethesda, MD 20892–9823; (240) 669–5044; *nv19q@nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: August 26, 2015.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015–21481 Filed 8–28–15; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Center for Scientific Review; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR Panel: Pregnancy in Women with Disabilities.

*Date:* September 21, 2015.

*Time:* 2:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Delia Olufokunbi Sam, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3158, MSC 7770, Bethesda, MD 20892, 301–435–0684, *olufokunbisamd@csr.nih.gov*.

*Name of Committee:* Emerging Technologies and Training Neurosciences Integrated Review Group, Bioengineering of Neuroscience, Vision and Low Vision Technologies Study Section.

*Date:* September 29, 2015.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* St. Gregory Luxury Hotel & Suites, 2033 M Street NW., Washington, DC 20036.

*Contact Person:* Robert C Elliott, Ph.D., Scientific Review Officer, Center for